Edwards Lifesciences (EW) Leases (2019 - 2026)

Edwards Lifesciences has reported Leases for 8 years, with the latest figure at $99.3 million in Q1 2026.

• For the quarter ending Q1 2026, Leases rose 2.48% year-over-year to $99.3 million; the trailing twelve-month figure through Mar 2026 stood at $99.3 million (up 2.48% YoY), and the FY2025 full-year result was $102.7 million, up 4.58% from the prior year.
• Leases for Q1 2026 stood at $99.3 million, down from $102.7 million in the prior quarter.
• The five-year high for Leases was $104.4 million in Q3 2024, with the low at $84.2 million in Q2 2022.
• Average Leases over 5 years is $93.6 million, with a median of $92.8 million recorded in 2024.
• Year-over-year, Leases declined 8.56% in 2023 and climbed 16.35% in 2024.
• Tracing EW's Leases over 5 years: stood at $92.3 million in 2022, then decreased by 8.56% to $84.4 million in 2023, then climbed by 16.35% to $98.2 million in 2024, then increased by 4.58% to $102.7 million in 2025, then slipped by 3.31% to $99.3 million in 2026.
• The last three Leases figures came in at $99.3 million (Q1 2026), $102.7 million (Q4 2025), and $96.5 million (Q3 2025), per Business Quant data.

Peer Comparison